Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00016224 | Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00096395 | Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jun 13, 2013 | clinicaltrials |
| NCT00002478 | Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00369954 | Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin | withdrawn | Phase 2 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Jun 10, 2013 | clinicaltrials |
| NCT00006043 | Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00002474 | Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer | completed | Phase 2 | — | Loyola UniversityOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00017017 | CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00006028 | Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | May 27, 2013 | clinicaltrials |
| NCT00583622 | Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2013 | clinicaltrials |
| NCT00117442 | A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood | completed | Phase 2 | 61 | AmgenINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT01383408 | Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection | terminated | Phase 2 | 752 | Schillerhoehe HospitalOTHER | 1 | May 7, 2013 | clinicaltrials |
| NCT00003425 | Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | completed | Phase 1 / Phase 2 | 25 | University of KentuckyOTHER | 1 | Apr 26, 2013 | clinicaltrials |
| NCT00003944 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Apr 17, 2013 | clinicaltrials |
| NCT00003386 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00004037 | Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006812 | Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00023907 | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00003408 | Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | completed | Phase 2 | 40 | Cancer Treatment Centers of AmericaOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00026091 | Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00091195 | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer | terminated | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00003173 | High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT00004066 | Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma | completed | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT00041041 | Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00003136 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 11 | University of ChicagoOTHER | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00003778 | Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00523809 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2013 | clinicaltrials |
| NCT00036751 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00081276 | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00083928 | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | completed | Phase 2 | 60 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00016289 | Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00551122 | Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors(GemTIP) | unknown | Phase 1 / Phase 2 | 23 | University of SouthamptonOTHER | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | completed | Phase 1 / Phase 2 | 138 | AbbVie (prior sponsor, Abbott)INDUSTRY | 9 | Jan 18, 2013 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00107445 | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00050414 | A Study of Trabectedin in Patients With Advanced Ovarian Cancer | completed | Phase 2 | 147 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jan 10, 2013 | clinicaltrials |
| NCT00396591 | AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | completed | Phase 2 | 16 | SanofiINDUSTRY | 3 | Jan 10, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | completed | Phase 2 | 68 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 4, 2013 | clinicaltrials |
| NCT00327444 | Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | completed | Phase 2 / Phase 3 | 58 | SanofiINDUSTRY | 9 | Jan 1, 2013 | clinicaltrials |
| NCT00610714 | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer(OVERT-1) | completed | Phase 2 | 211 | AstraZenecaINDUSTRY | 12 | Dec 18, 2012 | clinicaltrials |
| NCT00181688 | Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Dec 5, 2012 | clinicaltrials |
| NCT00316173 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | completed | Phase 2 | 77 | GlaxoSmithKlineINDUSTRY | 2 | Nov 27, 2012 | clinicaltrials |
| NCT00840450 | Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | terminated | Phase 2 | 14 | NYU Langone HealthOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT01724944 | LYmphadenectomy After NeoAdjuvant Chemotherapy(LYANA) | unknown | Phase 1 / Phase 2 | 65 | Catholic University of the Sacred HeartOTHER | 1 | Nov 12, 2012 | clinicaltrials |
| NCT00002671 | Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00005051 | Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00861120 | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type(PaLiDo) | completed | Phase 2 | 33 | Vejle HospitalOTHER | 4 | Oct 26, 2012 | clinicaltrials |
| NCT00078845 | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2013source: clinicaltrials